Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1972 2
1975 1
1976 1
1977 4
1978 3
1979 2
1980 6
1981 8
1982 7
1983 8
1984 7
1985 2
1986 4
1987 6
1988 8
1989 1
1990 8
1991 3
1992 3
1993 2
1995 1
1996 2
1997 1
1998 3
1999 1
2000 2
2001 3
2002 2
2003 3
2004 3
2005 3
2006 3
2007 4
2008 7
2009 2
2010 2
2011 6
2012 7
2013 6
2014 8
2015 3
2016 8
2017 5
2018 2
2019 6
2020 4
2021 9
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

180 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S. Le Q, et al. Among authors: loken mr. Clin Cancer Res. 2021 Oct 15;27(20):5718-5730. doi: 10.1158/1078-0432.CCR-21-1546. Epub 2021 Aug 11. Clin Cancer Res. 2021. PMID: 34380639
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.
Kaeding AJ, Barwe SP, Gopalakrishnapillai A, Ries RE, Alonzo TA, Gerbing RB, Correnti C, Loken MR, Broderson LE, Pardo L, Le QH, Tang T, Leonti AR, Smith JL, Chou CK, Xu M, Triche T, Kornblau SM, Kolb EA, Tarlock K, Meshinchi S. Kaeding AJ, et al. Among authors: loken mr. Blood Adv. 2021 May 11;5(9):2350-2361. doi: 10.1182/bloodadvances.2021004424. Blood Adv. 2021. PMID: 33938941 Free PMC article.
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. Tarlock K, et al. Among authors: loken mr. Blood. 2021 Sep 30;138(13):1137-1147. doi: 10.1182/blood.2020009652. Blood. 2021. PMID: 33951732 Clinical Trial.
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Pollard JA, et al. Among authors: loken mr. J Clin Oncol. 2021 Oct 1;39(28):3149-3160. doi: 10.1200/JCO.20.03048. Epub 2021 May 28. J Clin Oncol. 2021. PMID: 34048275 Clinical Trial.
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.
van der Velden VHJ, Preijers F, Johansson U, Westers TM, Dunlop A, Porwit A, Béné MC, Valent P, Te Marvelde J, Wagner-Ballon O, Oelschlaegel U, Saft L, Kordasti S, Ireland R, Cremers E, Alhan C, Duetz C, Hobo W, Chapuis N, Fontenay M, Bettelheim P, Eidenshink-Brodersen L, Font P, Loken MR, Matarraz S, Ogata K, Orfao A, Psarra K, Subirá D, Wells DA, Della Porta MG, Burbury K, Bellos F, Weiß E, Kern W, van de Loosdrecht A. van der Velden VHJ, et al. Among authors: loken mr. Cytometry B Clin Cytom. 2021 Dec 11. doi: 10.1002/cyto.b.22046. Online ahead of print. Cytometry B Clin Cytom. 2021. PMID: 34894176
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.
van de Loosdrecht AA, Kern W, Porwit A, Valent P, Kordasti S, Cremers E, Alhan C, Duetz C, Dunlop A, Hobo W, Preijers F, Wagner-Ballon O, Chapuis N, Fontenay M, Bettelheim P, Eidenschink-Brodersen L, Font P, Johansson U, Loken MR, Te Marvelde JG, Matarraz S, Ogata K, Oelschlaegel U, Orfao A, Psarra K, Subirá D, Wells DA, Béné MC, Della Porta MG, Burbury K, Bellos F, van der Velden VHJ, Westers TM, Saft L, Ireland R. van de Loosdrecht AA, et al. Among authors: loken mr. Cytometry B Clin Cytom. 2021 Dec 13. doi: 10.1002/cyto.b.22044. Online ahead of print. Cytometry B Clin Cytom. 2021. PMID: 34897979
Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromes.
Cutler JA, Pugsley HR, Bennington R, Fritschle W, Hartmann L, Zaidi N, Menssen AJ, Singleton TP, Xu D, Loken MR, Wells DA, Brodersen LE, Zehentner BK. Cutler JA, et al. Among authors: loken mr. Cytometry B Clin Cytom. 2021 Nov 13. doi: 10.1002/cyto.b.22036. Online ahead of print. Cytometry B Clin Cytom. 2021. PMID: 34773362
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.
van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM. van de Loosdrecht AA, et al. Among authors: loken mr. Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Leuk Lymphoma. 2013. PMID: 22916713 Review.
180 results